- The trend backdrop is active with a 12-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
ZYDUSLIFE
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Zydus Lifesciences Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
1,114 INR
-1.0%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 12.9% above the Trend Line and sits at 80.8% of its 52-week range. The latest completed week returned -1.0%, after a -3.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 47/100. Near-term considerations: volume confirmation is below normal.
Setup score
66
out of 100
Latest Close
1,114 INR
7 Aug 2026
1W Return
-1.0%
latest completed week
4W Return
-3.1%
short-term follow-through
12W Return
10.1%
quarterly tape
Trend Breadth
50.0%
26 of 52 weeks active
Volume Ratio
0.8x
vs 13-week average
- No major top-level risk cluster is currently dominant.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-1.0%
Latest completed week; four-week move -3.1%.
Indicator stack
69/67
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Positive 56.96%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
47/100
26 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 12.9% above the Trend Line and sits at 80.8% of its 52-week range. The latest completed week returned -1.0%, after a -3.1% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.9312-week average 0.68
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.93Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -3.1% over four weeks, 10.1% over 12 weeks, and 19.0% over one year. The current trend has remained active for 12 consecutive weeks.
Performance by holding period
Active trend streak12 weeks
Active weeks in one year26
Trend breadth50.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.08Latest activity-pressure read.
Pressure change-28.1%Four-week change in activity pressure.
Leadership14.52Latest relative-leadership reading.
RS change-33.2%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 94%
Model confidence 88%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength67/100Blend of value, momentum, and quality. Underlying universe rank 34; rank 1 is best.
Value35/100Relative valuation strength. Underlying universe rank 66; rank 1 is best.
Quality78/100Profitability and accounting quality. Underlying universe rank 23; rank 1 is best.
Momentum79/100Medium-term price momentum. Underlying universe rank 22; rank 1 is best.
Growth69/100Revenue and earnings growth. Underlying universe rank 32; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework69/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 22.4x Price divided by trailing earnings.
- Price / sales
- 4.1x Market value relative to trailing revenue.
- EV / EBITDA
- 15.0x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -0.4% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 72.9% Gross profit retained from each unit of revenue.
- Operating margin
- 23.8% Operating profit retained from revenue.
- Free-cash-flow margin
- -2.1% Free cash flow generated from revenue.
- Return on invested capital
- 12.4% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 18.4% Latest one-year revenue growth.
- EPS growth
- 11.4% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -110.9% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.1% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.1% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.4x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment47/100
Weighted news tone is neutral across 26 relevant articles.
3 positive · 22 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-5.6%Distance below the 52-week high.
13-week volatility2.8%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher15 of 2611 weeks finished lower.
Best week+7.6%Week of 15 May.
Worst week-3.8%Week of 1 May.
Latest week-1.0%Week of 7 Aug.
Shape of recent returns
Strong gains3
Modest gains12
Flat weeks0
Modest losses11
Sharp losses0
Recent vol2.8%13-week weekly-return volatility.
Base vol2.7%52-week weekly-return volatility.
Up/down split27/24Count of positive and negative weeks in the 52-week window.
Average skew2.4% / -1.9%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank72 / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank59 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape69/100
Trend, activity pressure, participation, and risk combine to a 69/100 tape read.
Indicator analysis90/100Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.
Activity pressure 0.93; No reversal markers Next-Week ExpectancyPositive 56.96%Next-week expectancy is positive with a 56.96% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors64/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 7 SVQF69/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 495.5 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment47/100Weighted news tone is neutral across 26 relevant articles.
Zydus Lifesciences reschedules Motilal Oswal investor conference to Aug 17 Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 1,114 INR | -1.0% | 987.1 INR | 925.5 INR | 1.08 | 14.52 | 4.8M | On |
| 31 Jul 2026 | 1,126 INR | 1.6% | 979.8 INR | 922.5 INR | 1.32 | 17.01 | 3.9M | On |
| 24 Jul 2026 | 1,109 INR | -3.0% | 972.8 INR | 919.4 INR | 1.48 | 18.63 | 4.9M | On |
| 17 Jul 2026 | 1,143 INR | -0.6% | 966.2 INR | 916.3 INR | 1.60 | 19.85 | 6.9M | On |
| 10 Jul 2026 | 1,150 INR | 0.9% | 958.8 INR | 912.9 INR | 1.51 | 21.73 | 7.9M | On |
| 3 Jul 2026 | 1,140 INR | 3.6% | 951.5 INR | 909.2 INR | 1.46 | 20.87 | 1.9M | On |
| 26 Jun 2026 | 1,100 INR | 2.9% | 944.5 INR | 905.6 INR | 1.47 | 18.23 | 0 | On |
| 19 Jun 2026 | 1,070 INR | -3.2% | 939.3 INR | 902.1 INR | 1.65 | 15.60 | 887.2K | On |
| 12 Jun 2026 | 1,105 INR | 1.4% | 934.4 INR | 898.8 INR | 1.85 | 21.76 | 872.2K | On |
| 5 Jun 2026 | 1,089 INR | 1.0% | 929.1 INR | 895.2 INR | 1.96 | 21.82 | 919.2K | On |
| 29 May 2026 | 1,078 INR | 3.7% | 924.2 INR | 891.3 INR | 1.84 | 20.15 | 11.0M | On |
| 22 May 2026 | 1,039 INR | 2.7% | 920.8 INR | 887.7 INR | 1.46 | 15.49 | 23.9M | On |
| 15 May 2026 | 1,012 INR | 7.6% | 919.7 INR | 884.2 INR | 1.19 | 13.27 | 9.0M | Off |
| 8 May 2026 | 940.0 INR | 5.4% | 918.9 INR | 880.8 INR | 0.91 | 3.30 | 3.4M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.